Dyne Therapeutics Newsroom

Dyne Therapeutics(DYN.US) Officer Sells US$4.05 Million in Common Stock

$Dyne Therapeutics(DYN.US)$ Officer Scalzo Richard William sold 126.07K shares of common stock on Sep 6, 2024 at an average price of $32.15 for a total value of $4.05 million.Source: Announcement

Futu NewsSep 11 04:11

Form 144 | Dyne Therapeutics(DYN.US) Officer Proposes to Sell 4.24 Million in Common Stocks

SEC FILLINGS DISCLOSED/ Sep 6, $Dyne Therapeutics(DYN.US)$ Officer Scalzo Richard William intends to sell 126.07K shares of its common stock on Aug 19, with a total market value of approximately $4.24

Futu NewsSep 7 04:26

CEO, President & Director of Dyne Therapeutics John Cox Buys 640% More Shares

Yahoo FinanceSep 6 18:39

Form 144 | Dyne Therapeutics(DYN.US) Officer Proposes to Sell 5.61 Million in Common Stocks

SEC FILLINGS DISCLOSED/ Sep 5, $Dyne Therapeutics(DYN.US)$ Officer McNeill Jonathan intends to sell 166.77K shares of its common stock on Sep 5, with a total market value of approximately $5.61

Futu NewsSep 6 04:49

H.C. Wainwright Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Maintains Target Price $55

H.C. Wainwright analyst Andrew Fein maintains $Dyne Therapeutics(DYN.US)$ with a buy rating, and maintains the target price at $55.According to TipRanks data, the analyst has a success rate of 46.2%

Futu NewsSep 5 19:34 · Ratings

Dyne Therapeutics Insider Bought Shares Worth $1,057,216, According to a Recent SEC Filing

MT NewswiresSep 5 05:46

A Quick Look at Today's Ratings for Dyne Therapeutics(DYN.US), With a Forecast Between $50 to $55

On Sep 04, major Wall Street analysts update their ratings for $Dyne Therapeutics(DYN.US)$, with price targets ranging from $50 to $55.Morgan Stanley analyst Michael Ulz maintains with a buy rating,

Futu NewsSep 4 21:00 · Ratings

Buy Rating Affirmed Amidst Dose Adjustments and Promising Trial Results for Dyne Therapeutics

TipRanksSep 4 10:35 · Ratings

Small U.S. Stocks Decrease; Dyne Therapeutics Takes Biggest Hit

Dow JonesSep 4 04:20

Oppenheimer Reiterates Outperform on Dyne Therapeutics, Maintains $55 Price Target

Analyst UpgradesSep 4 01:52

Dyne Therapeutics Analyst Ratings

BenzingaSep 4 01:50 · Ratings

Muscle Disease Drug Developer Dyne Therapeutics Stock Plunges After Updated Data From Duchenne Muscular Dystrophy

Yahoo FinanceSep 4 00:37

Dyne Therapeutics (DYN) Receives a Buy From Stifel Nicolaus

TipRanksSep 3 22:35 · Ratings

Vaxcyte PCVX Phase 1/2 Data; Dyne Therapeutics DYN Phase 1/2 DMD Results

BioPharmCatalystSep 3 20:26

Express News | Dyne Therapeutics Shares Down 29.5% Premarket After Co Reports Early-Mid-Stage Study Data for Muscular Disorder Drug

BreakingsSep 3 20:02

Express News | Dyne Therapeutics Inc - Dyne-251 Demonstrates Favorable Safety Profile

BreakingsSep 3 18:31

Press Release: Dyne Therapeutics Announces Key Leadership Appointments

Dow JonesSep 3 18:31

Express News | Dyne Therapeutics Inc - Initiating Registrational Cohorts With Update on Path to Registration by Year-End 2024

BreakingsSep 3 18:30

Express News | Dyne Therapeutics Inc - to Provide Registration Update by Year-End

BreakingsSep 3 18:30

Dyne Therapeutics Announces New Clinical Data From Phase 1/2 DELIVER Trial of DYNE-251 in Duchenne Muscular Dystrophy Demonstrating Unprecedented Dystrophin Expression and Functional Improvement in Multiple Cohorts

GlobeNewswireSep 3 18:30